Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling

Approximately 20,000 patients per year are diagnosed with esophageal adenocarcinoma (EAC) and malignant pleural mesothelioma (MPM); fewer than 20% survive 5 years. Effective therapeutic strategies are limited although patients receive a combination of chemotherapeutics. These tumors harbor thousands...

Descripción completa

Detalles Bibliográficos
Autores principales: Surman, Deborah R., Xu, Yuan, Lee, Min-Jung, Trepel, Jane, Brown, Kate, Ramineni, Maheshwari, Splawn, Taylor G., Diggs, Laurence P., Hodges, H. Courtney, Davis, Jeremy L., Lee, Hyun-Sung, Burt, Bryan M., Ripley, Robert Taylor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Models and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338890/
https://www.ncbi.nlm.nih.gov/pubmed/34088830
http://dx.doi.org/10.1158/1535-7163.MCT-20-0887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338890/
https://www.ncbi.nlm.nih.gov/pubmed/34088830
http://dx.doi.org/10.1158/1535-7163.MCT-20-0887

Ejemplares similares